Genfit price target raised to $13 from $11 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Genfit to $13 from $11 and keeps a Buy rating on the shares after the company’s partner Ipsen announced the FDA has granted accelerated approval of Iqirvo once-daily for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid. The firm says Iqirvo has a favorable label to support trial and uptake.